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Letter to the Editor:  
Clinical benefits of ezetimibe; absence of proof is just that. 
Sheila A Doggrell PhD DSc, School of Biomedical Sciences, Faculty of Health, Queensland University 
of Technology, GPO 2434, QLD 4001, Brisbane, Australia 
sheila.doggrell@qut.edu.au  
 
In 2012, I wrote a review of ezetimibe for the journal Expert Opinion on Pharmacology where I gave 
my opinion as ‘Ezetimibe alone or in the presence of simvastatin lowers LDL cholesterol.  However, 
ezetimibe alone or in the presence of simvastatin has not been shown to have any irrefutable 
beneficial effects on atherosclerosis or cardiovascular morbidity and mortality.   Thus, until/unless 
the use of ezetimibe is clearly shown to improve clinical outcomes, its use should be largely 
restricted to clinical trials investigating clinical outcomes, and ezetimibe should not be used routinely 
in everyday practice’ [1].   
 
An editorial in the journal argued that ‘Clinical benefits of ezetimibe use: is absence of proof, proof 
of absence?’ [2].  In my response, I argue that absence of proof is just that.  Thus, four clinical trials 
(ARBITER 6-HALTS, ENHANCE, VYCTOR and SANDS) have failed to detect any effect of ezetimibe on 
carotid intima thickness.  In ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment 
Effects of Reducing cholesterol 6 – HDL and LDL Treatment Strategies), no significant reduction of 
carotid-intima thickness was observed with ezetimibe after 14 months [3].  In ENHANCE (Ezetimibe 
and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) study, the primary 
outcome measure of intima-media thickness of the carotid artery was increased and ezetimibe had 
no effect [4].  SANDS (Stop Atherosclerosis in Native Diabetic Study) showed a similar reduction of 
carotid-intima thickness with simvastatin alone and simvastatin in combination with ezetimibe [5].  
SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) did not demonstrate any effect of ezetimibe on 
cardiovascular events or aortic-valve replacement, and SHARP (Study of Heart and Renal Protection) 
did not demonstrate a reduction in major atherosclerotic events [1].   
In 2013, another study has failed to show a beneficial clinical outcome with ezetimibe.  Thus, 
ezetimibe, in the presence of a statin, did not reduce all-cause mortality in 3827 subjects with 
cardiovascular disease [6].  In conclusion, the absence of proof of any beneficial clinical outcomes is 
mounting for ezetimibe.    
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